Published in J Neuropathol Exp Neurol on April 01, 2009
Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol (2012) 0.85
Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis (2013) 0.82
Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments. Neuropsychiatr Dis Treat (2013) 0.82
Synthesis and preliminary studies of a novel negative allosteric modulator [(11)C]QCA for imaging of metabotropic glutamate receptor 2. ACS Chem Neurosci (2017) 0.81
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates. Front Neurol (2014) 0.79
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias. Curr Neuropharmacol (2016) 0.75
Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. ACS Med Chem Lett (2017) 0.75
Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain (2007) 4.36
VPS35 mutations in Parkinson disease. Am J Hum Genet (2011) 4.16
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci (2005) 2.36
Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov (2006) 2.23
Essential tremor course and disability: A clinicopathologic study of 20 cases. Neurology (2004) 2.18
Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci (2006) 2.09
Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2004) 1.77
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain (2007) 1.66
Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord (2013) 1.64
The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A (2004) 1.59
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
Mortality in Parkinson's disease. Mov Disord (2010) 1.51
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain (2009) 1.44
Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms. Mov Disord (2012) 1.44
Reduced noradrenaline, but not dopamine and serotonin in motor thalamus of the MPTP primate: relation to severity of parkinsonism. J Neurochem (2013) 1.43
Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol (2009) 1.39
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics (2010) 1.37
Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem (2003) 1.28
High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging (2008) 1.26
Glucosidase-beta variations and Lewy body disorders. Parkinsonism Relat Disord (2008) 1.24
p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem (2008) 1.21
LINGO1 rs9652490 is associated with essential tremor and Parkinson disease. Parkinsonism Relat Disord (2009) 1.18
Canadian Guidelines on Parkinson's Disease. Can J Neurol Sci (2012) 1.15
Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. Prostaglandins Leukot Essent Fatty Acids (2009) 1.14
FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. Mov Disord (2009) 1.10
Torpedoes in Parkinson's disease, Alzheimer's disease, essential tremor, and control brains. Mov Disord (2009) 1.09
Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy. Parkinsonism Relat Disord (2007) 1.08
Defective dentate nucleus GABA receptors in essential tremor. Brain (2011) 1.07
ATP13A2 variability in Parkinson disease. Hum Mutat (2009) 1.05
Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function. Mol Neurodegener (2011) 1.05
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain (2004) 1.02
STX6 rs1411478 is not associated with increased risk of Parkinson's disease. Parkinsonism Relat Disord (2013) 1.01
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis (2003) 1.01
Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab (2013) 1.01
Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism Relat Disord (2011) 1.00
Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord (2002) 1.00
Parkinson's disease, stroke, and related epidemiology. Mov Disord (2005) 0.98
Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. Neurochem Int (2009) 0.98
DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS One (2011) 0.98
Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol (2011) 0.97
Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain (2009) 0.96
Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology (2009) 0.95
Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch Neurol (2010) 0.95
Clinical-pathological study of levodopa complications. Mov Disord (2002) 0.94
Iron, copper, and zinc distribution of the cerebellum. Cerebellum (2009) 0.94
Brain iron detected by SWI high pass filtered phase calibrated with synchrotron X-ray fluorescence. J Magn Reson Imaging (2010) 0.94
Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem Int (2006) 0.93
Anomalies of asymmetry of clinical signs in parkinsonism. Mov Disord (2004) 0.93
Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer's disease. Eur J Neurosci (2010) 0.93
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging (2007) 0.93
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int (2006) 0.92
Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord (2003) 0.92
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology (2010) 0.92
Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage. Stroke (2011) 0.91
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis (2004) 0.91
In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol Pharmacol (2011) 0.91
Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis (2007) 0.89
Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem (2014) 0.89
Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol (2006) 0.89
ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier. J Alzheimers Dis (2012) 0.89
Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol (2002) 0.88
Phactr2 and Parkinson's disease. Neurosci Lett (2009) 0.87
Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline. Arch Neurol (2006) 0.87
Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J Neurochem (2010) 0.87
Impact of ω-3 fatty acids in Parkinson's disease. Ageing Res Rev (2011) 0.86
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys. Mov Disord (2005) 0.86
Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens. J Neurochem (2007) 0.85
Essential tremor is not a neurodegenerative disease. Neurodegener Dis Manag (2012) 0.85
Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord (2004) 0.85
Decreased drebrin mRNA expression in Alzheimer disease: correlation with tau pathology. J Neurosci Res (2008) 0.85
Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease. J Alzheimers Dis (2011) 0.85
Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid. Neurobiol Dis (2009) 0.84
Histamine N-methyltransferase Thr105Ile is not associated with Parkinson's disease or essential tremor. Parkinsonism Relat Disord (2009) 0.84
Increased LINGO1 in the cerebellum of essential tremor patients. Mov Disord (2014) 0.84
The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. J Neuroinflammation (2011) 0.84
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology (2003) 0.84
GCH1 in early-onset Parkinson's disease. Mov Disord (2009) 0.83
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse (2006) 0.83
Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov Disord (2003) 0.83